Inna N. Vasil’Eva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Inna N. Vasil’Eva has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Annette Pulcherie Iloki-Lewis
Department of Medicine and Health Sciences, University of Sonora, Luis Encinas y Rosales, Centro, Hermosillo 83000, Sonora, Mexico
1 shared publication - Ekaterina D. Mironova
Sechenov University, Russia
1 shared publication - Juan Carlos Gálvez-Ruiz
Department of Biological Chemical Sciences, University of Sonora, Luis Encinas y Rosales, Centro, Hermosillo 83000, Sonora, Mexico
1 shared publication - Lidianys María Lewis-Luján
Department of Biological Chemical Sciences, University of Sonora, Luis Encinas y Rosales, Centro, Hermosillo 83000, Sonora, Mexico
1 shared publication - Maxim Victorovich Trushin
Kazan Federal University Kazan Russia
1 shared publication - Mikhail Alekseevich Osadchuk
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
1 shared publication
Latest Publications
- Open Access
- 9 December 2025
- Published by MDPI AG in Preprints.org
Molecular Crosstalk of the Motilin–Somatostatin–VEGF Axis in Duodenal Dysfunction Underlying IBS-C and Functional Dyspepsia
The duodenal mucosa plays a pivotal role in gastrointestinal physiology through its endocrine cells (ECs), which secrete key regulatory factors including motilin (MLN), somatostatin (SS), and vascular endothelial growth factor (VEGF). Alterations in the expression of these mediators have been implicated in the pathogenesis of irritable bowel syndrome with constipation (IBS-C) and its overlap with functional dyspepsia (FD). In this study, immunohistochemical and morphometric analyses were performed on duodenal retrobulbar part biopsies obtained from patients with IBS-C, IBS-C combined with FD, and healthy controls. The results demonstrated a significant reduction in MLN-secreting ECs, accompanied by increased SS- and VEGF-positive ECs in IBS-C with FD patients compared to other groups. These endocrine alterations were associated with more severe abdominal pain, higher body mass index, and greater anxiety and depression scores. The findings highlight the contribution of duodenal EC dysfunction to impaired motility, visceral hypersensitivity, and low-grade inflammation, supporting the concept of the duodenum as a critical neuroendocrine hub within the gut–brain axis. This study underscores the relevance of MLN, SS, and VEGF as potential biomarkers and therapeutic targets in IBS-C and FD comorbidity.
- 9 December 2025
- Published by MDPI AG in Preprints.org
Open AccessMolecular Crosstalk of the Motilin–Somatostatin–VEGF Axis in Duodenal Dysfunction Underlying IBS-C and Functional Dyspepsia
The duodenal mucosa plays a pivotal role in gastrointestinal physiology through its endocrine cells (ECs), which secrete key regulatory factors including motilin (MLN), somatostatin (SS), and vascular endothelial growth factor (VEGF). Alterations in the expression of these mediators have been implicated in the pathogenesis of irritable bowel syndrome with constipation (IBS-C) and its overlap with functional dyspepsia (FD). In this study, immunohistochemical and morphometric analyses were performed on duodenal retrobulbar part biopsies obtained from patients with IBS-C, IBS-C combined with FD, and healthy controls. The results demonstrated a significant reduction in MLN-secreting ECs, accompanied by increased SS- and VEGF-positive ECs in IBS-C with FD patients compared to other groups. These endocrine alterations were associated with more severe abdominal pain, higher body mass index, and greater anxiety and depression scores. The findings highlight the contribution of duodenal EC dysfunction to impaired motility, visceral hypersensitivity, and low-grade inflammation, supporting the concept of the duodenum as a critical neuroendocrine hub within the gut–brain axis. This study underscores the relevance of MLN, SS, and VEGF as potential biomarkers and therapeutic targets in IBS-C and FD comorbidity.